R1 pancreatic cancer patients benefit from chemoradiation when initiation of adjuvant therapy is delayed

Adjuvant chemotherapy (AC) following pancreaticoduodenectomy (PD) for pancreas cancer (PDAC) has been demonstrated to improve survival. However, the optimal adjuvant treatment (AT) regimen for R1-margin patients remains unclear. This retrospective study investigates the impact of AC vs. adjuvant che...

Full description

Saved in:
Bibliographic Details
Published in:Surgical oncology 2023-08, Vol.49, p.101961-101961, Article 101961
Main Authors: Chirban, Ariana M., Vega, Eduardo A., Kutlu, Onur C., Mellado, Sebastian, Kozyreva, Olga, Zauls, Andris J., Panettieri, Elena, Salirrosas, Oscar, Freeman, Richard, Conrad, Claudius
Format: Article
Language:English
Subjects:
Adjuvant chemoradiotherapy
Adjuvant chemotherapy
Carcinoma, Pancreatic Ductal - therapy
Chemoradiotherapy, Adjuvant
Chemotherapy, Adjuvant
Combined Modality Therapy
Humans
NCDB
Overall survival
Pancreatic ductal adenocarcinoma
Pancreatic Neoplasms
Pancreatic Neoplasms - therapy
Pancreaticoduodenectomy
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adjuvant chemotherapy (AC) following pancreaticoduodenectomy (PD) for pancreas cancer (PDAC) has been demonstrated to improve survival. However, the optimal adjuvant treatment (AT) regimen for R1-margin patients remains unclear. This retrospective study investigates the impact of AC vs. adjuvant chemoradiotherapy (ACRT) on survival (OS). The NCDB was queried for patients with PDAC who underwent PD between 2010 and 2018. Patients were divided into, (A) AC
ISSN:0960-7404
1879-3320
DOI:10.1016/j.suronc.2023.101961